| Name | complex is |
|---|---|
| Synonyms | 39kD; CI 39kD; Complex I; Complex I 39kD; NADH dehydrogenase (ubiquinone) Fe S protein 2 like; NADH ubiquinone oxidoreductase 39 kDa subunit mitochondrial; NADH ubiquinone oxidoreductase 39 kDa subunit; NDUFA 9… |
| Name | strychnine |
|---|---|
| CAS | strychnidin-10-one |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 8397587 | Nichols AC, Yielding KL: Anticonvulsant activity of antagonists for the -associated binding site. Mol Chem Neuropathol. 1993 Aug;19(3):269-82. Coupled to the (NMDA) receptor-channel complex is a strychnine-insensitive binding site for |
31(0,1,1,1) | Details |
| 9792190 | Nagata Y, Uehara T, Kitamura Y, Nomura Y, Horiike K: content and D-[3H] serine binding in the brain regions of the senescence-accelerated mouse. Mech Ageing Dev. 1998 Aug 14;104(2):115-24. binds to strychnine-insensitive binding sites of the (NMDA) receptor complex, and enhances binding to the receptor complex. These results support the view that a decrease of NMDA receptor complex is involved in the age-related neural dysfunction of SAMP8 mice. |
1(0,0,0,1) | Details |
| 8531091 | Witkin JM, Brave S, French D, Geter-Douglass B: Discriminative stimulus effects of R-(+)-3-amino-1-hydroxypyrrolid-2-one, [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther. 1995 Dec;275(3):1267-73. The strychnine-insensitive site on the (NMDA) receptor complex is a target for development of a host of therapeutic agents including anxiolytics, antidepressants, antiepileptics, anti-ischemics and cognitive enhancers. |
31(0,1,1,1) | Details |
| 7813551 | Long JB, Skolnick P: 1-Aminocyclopropanecarboxylic acid protects against dynorphin A-induced spinal injury. Eur J Pharmacol. 1994 Aug 22;261(3):295-301. The protective effects of a variety of competitive and non-competitive (NMDA) receptor antagonists indicate that activation of the NMDA receptor complex is essential for dynorphin A-induced spinal cord injury. 1-Aminocyclopropanecarboxylic acid (ACPC) is a high affinity, partial agonist at strychnine-insensitive glycine receptors associated with the NMDA receptor complex. |
31(0,1,1,1) | Details |
| 9264101 | Decollogne S, Tomas A, Lecerf C, Adamowicz E, Seman M: NMDA receptor complex blockade by oral administration of comparison with MK-801. Pharmacol Biochem Behav. 1997 Sep;58(1):261-8. The ion channel of the (NMDA) receptor complex is subject to a voltage-dependent regulation by Mg2+ cations. An anticonvulsant effect of Mg2+ treatment is also observed with strychnine-induced convulsions but not with bicuculline-, picrotoxin-, or pentylenetetrazol-induced convulsions. |
1(0,0,0,1) | Details |
| 10587285 | File SE, Fluck E, Fernandes C: Beneficial effects of (bioglycin) on memory and attention in young and middle-aged adults. J Clin Psychopharmacol. 1999 Dec;19(6):506-12. The N-methyl D-aspartate receptor complex is involved in the mechanism of long-term potentiation, which is thought to be the biological basis of learning and memory. This complex can be manipulated in a number of ways, one of which is through the strychnine-insensitive glycine receptor coagonist site. |
1(0,0,0,1) | Details |
| 8169857 | Paul IA, Nowak G, Layer RT, Popik P, Skolnick P: Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther. 1994 Apr;269(1):95-102. Chronic (14 day) but not acute (1 day) treatment of mice with clinically active antidepressants produces a significant (approximately 1.8-4.3 fold) reduction in the potency of to inhibit [3H]-5,7-dichlorkynurenic acid (5,7-DCKA) binding to strychnine-insensitive glycine receptors in neocortical membranes. The ability of antidepressants drawn from every principal therapeutic class to effect adaptive changes in the N-methyl-D-aspartate receptor complex is consistent with the hypothesis that this ligand-gated ion channel serves as a final common pathway of antidepressant action and indicates that glutamatergic pathways may be involved in the pathophysiology of depression. |
1(0,0,0,1) | Details |
| 9215988 | Auer RN: Structural neurotoxicologic investigation of the antagonist 5-nitro-6,7-dichloroquinoxalinedione (ACEA-1021). Neurotoxicology. 1997;18(1):53-62. Since previous studies have shown anti-ischemic efficacy of this compound in focal, but not global ischemia, it appears that the therapeutic profile of this antagonist of the strychnine-insensitive site is similar, but the toxicologic structural profile is different, from NMDA receptor antagonists. This investigation used 38 Wistar rats to determine whether the structural toxicologic profile of a newly developed halogenated quinoxalinedione derivative, a pharmacologic antagonist of the site on the NMDA receptor complex, is identical to that seen with MK-801. |
1(0,0,0,1) | Details |
| 8096081 | Forsythe ID, Barnes-Davies M: The binaural auditory pathway: excitatory amino acid receptors mediate dual timecourse excitatory postsynaptic currents in the rat medial nucleus of the trapezoid body. Proc Biol Sci. 1993 Feb 22;251(1331):151-7. Other smaller EPSCS mediated by and non-NMDA receptors, and a strychnine-sensitive synaptic current, are also present. |
0(0,0,0,0) | Details |
| 9112643 | Nowak G: antagonists in the olfactory bulbectomy animal model of depression: effect on the cortical NMDA receptor complex. Pol J Pharmacol. 1996 Mar-Apr;48(2):137-43. We report that chronic administration of (20 mg/kg) and (10 mg/kg) did not reduced OB-induced hyperactivity, although these drugs reduced the potency of to inhibit [3H] 5,7-dichlorokynurenic acid (DCKA) binding to strychnine-insensitive sites of the NMDA receptor complex. |
0(0,0,0,0) | Details |